Badreddin Edris Spring Works Therapeutics, Inc. (SWTX) insider trading activity

Badreddin Edris is Chief Operating Officer of SpringWorks Therapeutics, Inc.. Currently has a direct ownership of 0 shares of SWTX, which is worth approximately $0. The most recent transaction as insider was on Jul 01, 2025, when has been sold 169,712 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Badreddin Edris Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 01 2025	SELL Sale (or disposition) back to the issuer	-	169,712 Reduced 100.0%	0 Common Stock
Mar 03 2025	SELL Open market or private sale	$1,093,400 $54.67 p/Share	20,000 Reduced 10.54%	169,712 Common Stock
Feb 10 2025	SELL Open market or private sale	$1,593,900 $53.13 p/Share	30,000 Reduced 13.65%	189,712 Common Stock
Jan 10 2025	BUY Grant, award, or other acquisition	-	27,023 Added 10.95%	219,712 Common Stock
Jan 06 2025	SELL Payment of exercise price or tax liability	$171,605 $38.86 p/Share	4,416 Reduced 2.24%	192,689 Common Stock
Jan 05 2025	SELL Payment of exercise price or tax liability	$212,374 $38.19 p/Share	5,561 Reduced 2.74%	197,105 Common Stock
Jan 04 2025	SELL Payment of exercise price or tax liability	$264,809 $38.19 p/Share	6,934 Reduced 3.31%	202,666 Common Stock
Dec 03 2024	SELL Open market or private sale	$840,200 $42.01 p/Share	20,000 Reduced 8.71%	209,600 Common Stock
Sep 03 2024	SELL Open market or private sale	$822,000 $41.1 p/Share	20,000 Reduced 8.01%	229,600 Common Stock
Jun 03 2024	SELL Open market or private sale	$817,200 $40.86 p/Share	20,000 Reduced 7.42%	249,600 Common Stock
Jan 08 2024	SELL Payment of exercise price or tax liability	$227,002 $41.53 p/Share	5,466 Reduced 1.99%	269,600 Common Stock
Jan 05 2024	SELL Payment of exercise price or tax liability	$169,643 $37.96 p/Share	4,469 Reduced 1.6%	275,066 Common Stock
Jan 04 2024	BUY Grant, award, or other acquisition	-	42,312 Added 13.15%	279,535 Common Stock
Jan 07 2023	SELL Payment of exercise price or tax liability	$39,166 $26.41 p/Share	1,483 Reduced 0.62%	237,223 Common Stock
Jan 06 2023	SELL Payment of exercise price or tax liability	$91,531 $27.52 p/Share	3,326 Reduced 1.37%	238,706 Common Stock
Jan 05 2023	BUY Grant, award, or other acquisition	-	33,994 Added 12.32%	242,032 Common Stock
Jan 07 2022	SELL Payment of exercise price or tax liability	$141,888 $56.06 p/Share	2,531 Reduced 0.77%	325,134 Common Stock
Jan 06 2022	BUY Grant, award, or other acquisition	-	26,124 Added 7.38%	327,665 Common Stock
Jul 01 2021	SELL Open market or private sale	$2,731,200 $85.35 p/Share	32,000 Reduced 9.59%	301,541 Common Stock
Jan 25 2021	SELL Open market or private sale	$2,690,240 $84.07 p/Share	32,000 Reduced 10.9%	261,542 Common Stock
Jan 07 2021	BUY Grant, award, or other acquisition	-	13,000 Added 4.24%	293,542 Common Stock

Also insider at

EWTX

Edgewise Therapeutics, Inc. Healthcare

Badreddin Edris

Chief Operating Officer

Stamford, CT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SWTX shares.

Notify only if

Value

Insider Trading

Get notified when an Spring Works Therapeutics, Inc. insider buys or sells SWTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to SpringWorks Therapeutics, Inc.

Track Activities on SWTX

Account